Long-term outcomes reveal metastatic risk in prostate cancer patients post radical prostatectomy, suggesting a need for adjuvant therapy.
In the ProtecT trial, the 15-year risk of metastasis or death after RP was a binary outcome defined by cribriform status. The concentration of risk in men with cribriform-positive, high-grade and/or pT3b tumours identifies a target population for adjuvant therapy trials, while supporting management de-escalation for most RP patients.
No takes yet. Share an insight, caveat, or question.
Sushentsev et al. (2026) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: